Gamida Cell (NASDAQ:GMDA) Upgraded to “Buy” at ValuEngine

Gamida Cell (NASDAQ:GMDA) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Thursday, ValuEngine reports.

Separately, Zacks Investment Research cut shares of Gamida Cell from a “hold” rating to a “sell” rating in a research note on Thursday, July 4th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $18.67.

Shares of NASDAQ:GMDA traded down $0.03 during trading on Thursday, reaching $3.62. The stock had a trading volume of 5,189 shares, compared to its average volume of 23,902. Gamida Cell has a 52 week low of $3.60 and a 52 week high of $15.41. The firm has a 50-day simple moving average of $5.17. The company has a debt-to-equity ratio of 0.36, a current ratio of 6.52 and a quick ratio of 6.52. The company has a market cap of $87.68 million and a PE ratio of -0.34.

Gamida Cell (NASDAQ:GMDA) last posted its earnings results on Tuesday, May 7th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.25). Equities research analysts anticipate that Gamida Cell will post -1.95 earnings per share for the current fiscal year.

Several institutional investors have recently modified their holdings of GMDA. Millennium Management LLC acquired a new stake in shares of Gamida Cell in the fourth quarter valued at approximately $210,000. FMR LLC acquired a new stake in shares of Gamida Cell in the fourth quarter valued at approximately $1,243,000. Norges Bank acquired a new stake in shares of Gamida Cell in the fourth quarter valued at approximately $88,000. Finally, Edmond DE Rothschild Holding S.A. acquired a new stake in shares of Gamida Cell in the first quarter valued at approximately $53,000. 1.72% of the stock is owned by institutional investors and hedge funds.

Gamida Cell Company Profile

Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.

Featured Story: Discover Your Risk Tolerance

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Gamida Cell (NASDAQ:GMDA)

Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.